Table 5 Overall change in monthly MHD, non-migraine headache days, and percentage reduction in monthly MHD
From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
|  | Galcanezumab 120 mg N = 135 | Galcanezumab 240 mg N = 135 |
|---|---|---|
Overall change from baseline in number of monthly MHD, mean (SD) | −5.6 (0.34) | −6.5 (0.33) |
Overall change from baseline in monthly non-migraine headache days, mean (SD) | −2.2 (0.3) | −2.1 (0.3) |
Overall change from baseline in number of days with acute medication use, mean (SD) | −5.1 (0.4) | −5.1 (0.4) |
Percentage of patients who had ≥30% reduction in MHD | 76.1% | 80.9% |
Percentage of patients who had ≥50% reduction in MHD | 65.6% | 73.7% |
Percentage of patients who had ≥75% reduction in MHD | 44.5% | 52.5% |
Percentage of patients who had 100% reduction in MHD | 21.4% | 21.8% |